[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-164765-105":53,"doc-detail-164765-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","template-letter-of-appeal-for-nonsegmental-vitiligo-opzelura","TEMPLATE LETTER OF APPEAL FOR NONSEGMENTAL VITILIGO - OPZELURA","","Template letter for appealing a prior authorization denial for OPZELURA® (ruxolitinib) cream 1.5% in patients with nonsegmental vitiligo. The document provides placeholders for payer and physician details, patient demographics, diagnosis codes, case identifiers, and an appeal addendum addressing the specific denial reason. It includes sections to describe patient background, clinical rationale for prescribing, prior treatment history, and a recommended justification for medical appropriateness, including coverage considerations and FDA-approved indication language. It also includes indication and safety information references to support the appeal packet.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/template-letter-of-appeal-for-nonsegmental-vitiligo-opzelura/164765/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/template-letter-of-appeal-for-nonsegmental-vitiligo-opzelura/164765.png","ImageObject",442,249,{"name":88,"@type":89},"Caleb Sterling","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-23","2026-08-31",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",6,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is the purpose of this template letter of appeal?","Question",{"text":109,"@type":110},"It provides a sample appeals letter template to help a payer review an appeal for OPZELURA in nonsegmental vitiligo and to address the stated denial reason.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What information must be customized before submitting the appeal?",{"text":114,"@type":110},"The prescriber must fill in bracketed placeholders such as physician and practice details, patient information, diagnosis code, and the specific denial reason, along with clinical and treatment history content.",{"name":116,"@type":107,"acceptedAnswer":117},"What clinical details should be included in the appeal?",{"text":118,"@type":110},"The letter should include patient background, the clinical rationale for prescribing OPZELURA (including confirmation of an FDA-approved indication and ruling out other causes of depigmentation when applicable), and a list of prior therapies with reasons for discontinuation.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},164765,1788160399,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":126,"read_time":76},962084925290,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TEMPLATE LETTER OF APPEAL FOR NONSEGMENTAL VITILIGO\nWhen a Prior Authorization is denied, it can be appealed following the health plan’s process for appeals. Please refer to the Prior Authorization denial letter to obtain the denial reason and information on the plan’s appeal submission process. \u000bThe denial reason should be directly addressed in the appeals letter.\nThe prescriber should refer to the Full Prescribing Information for OPZELURA® (ruxolitinib) cream 1.5% when determining whether the product is medically appropriate for a patient.\nThe following template letter is only intended as a SAMPLE Letter of Appeal for nonsegmental vitiligo and outlines the information a payer may need when \u000breviewing an appeal.\nThe prescriber is responsible for the content of this letter and may customize it as needed. Note that the bracketed information in magenta must be customized with the\u000bappropriate information.\nPlease see \u0013 HYPERLINK \"https://www.opzelura.com/prescribing-information.pdf\" \u0014Full Prescribing Information\u0015, including Boxed Warning,\nand \u0013 HYPERLINK \"https://www.opzelura.com/medication-guide.pdf\" \u0014Medication Guide\u0015 for OPZELURA.\n\u000f\nTEMPLATE LETTER OF APPEAL FOR NONSEGMENTAL VITILIGO\n\u003C\u003CPhysician’s Letterhead>>\n\u003C\u003CDate>>\n\u003C\u003CAttention: Payer Contact Name/Payer Department>>\n\u003C\u003CInsert Name of Health Insurance Company>>\n\u003C\u003CInsert Health Plan’s Address for Appeal Submissions>>\n\u003C\u003CCity, State, ZIP Code>>\nRE: Request for Appeal for OPZELURA® (ruxolitinib) cream 1.5%\nPatient: \u003C\u003CPatient Name>>\nDate of Birth: \u003C\u003CDate>>\nDiagnosis: Nonsegmental vitiligo \u003C\u003CICD-10-CM>>\nGroup/Policy Number: \u003C\u003CNumber>>\nPolicyholder: \u003C\u003CPolicyholder Name>>\nCase or Request ID: \u003C\u003CCase/request ID/reference # listed on PA denial letter>>\nTo Whom It May Concern:\nOn behalf of my patient, this letter is to appeal the denial of OPZELURA. The denial reason stated was \u003C\u003Cinsert coverage denial reason>>. I maintain that OPZELURA is the appropriate therapy for my patient.\nPatient Background\nMy patient has been in my care since \u003C\u003Cmonth year>>. \u000b\u000b\u003C\u003CInclude information such as patient’s current symptoms and condition, treatment goals for this patient, and/or impact on quality of life, social/emotional, and/or career, and daily living\u000bproblems.>>\nClinical Rationale\n\u003C\u003CInclude your clinical rationale and reasons for prescribing the product, highlighting factors leading you to recommend the use of this product, such as how OPZELURA allows for a targeted approach to treating the disease. Additionally, confirm that OPZELURA is being used for an FDA-approved indication. If applicable, rule out that other causes of depigmentation have been ruled out.>>\nPatient Treatment History\n\u003C\u003CInclude the list of prescription medications the patient has tried and failed that are related to their diagnosis and/or a justification of why these drugs are inadvisable due to ineffectiveness, contraindications, intolerance, and/or use in a sensitive area. Note that common step-through drugs include topical corticosteroids, such as clobetasone or triamcinolone, or a topical calcineurin inhibitor, such as tacrolimus or pimecrolimus, and/or phototherapies or bleaching agents. Note: Many plans do not require use of a TCS if the drug is to be used in sensitive areas.>>\n\u003C\u003CPhysician’s Letterhead>>\nPrevious Therapies: \t\tReasons for Discontinuation:\t\tDuration of Therapy:\n________________\t\t_______________________\t            ________________\n________________\t\t_______________________\t\t________________\n________________\t\t_______________________\t\t________________\n\u003C\u003CIf applicable, address body surface area:>> My patient has vitiligo located on \u003C\u003Cinsert location on the body>> with a total body surface area of \u003C\u003Center % of patient’s body surface area. Note that plans typically require a total body surface area of less than or equal to 10%>>.\n\u003C\u003CAddressing cosmetic use in your appeal:>> The Food and Drug Administration (FDA) granted OPZELURA a Priority Review designation for nonsegmental vitiligo, indicating that the FDA considers ","cbCaief4lr4fPe1W","https://ap.wps.com/l/cbCaief4lr4fPe1W","docx",47698,7,"English","# TEMPLATE LETTER OF APPEAL FOR NONSEGMENTAL VITILIGO - OPZELURA\n## Patient and Insurance Submission Details\n## Patient Background\n## Clinical Rationale\n## Patient Treatment History\n## Addressing Cosmetic Use in the Appeal\n## Contact and Signature Information\n## Indication\n## IMPORTANT SAFETY INFORMATION","[{\"question\":\"What is the purpose of this template letter of appeal?\",\"answer\":\"It provides a sample appeals letter template to help a payer review an appeal for OPZELURA in nonsegmental vitiligo and to address the stated denial reason.\"},{\"question\":\"What information must be customized before submitting the appeal?\",\"answer\":\"The prescriber must fill in bracketed placeholders such as physician and practice details, patient information, diagnosis code, and the specific denial reason, along with clinical and treatment history content.\"},{\"question\":\"What clinical details should be included in the appeal?\",\"answer\":\"The letter should include patient background, the clinical rationale for prescribing OPZELURA (including confirmation of an FDA-approved indication and ruling out other causes of depigmentation when applicable), and a list of prior therapies with reasons for discontinuation.\"}]","TEMPLATE LETTER OF APPEAL FOR NONSEGMENTAL VITILIGO - OPZELURA | DOCX"]